BR112015023481A2 - composição de lipossoma de liberação controlada de fármaco - Google Patents

composição de lipossoma de liberação controlada de fármaco

Info

Publication number
BR112015023481A2
BR112015023481A2 BR112015023481A BR112015023481A BR112015023481A2 BR 112015023481 A2 BR112015023481 A2 BR 112015023481A2 BR 112015023481 A BR112015023481 A BR 112015023481A BR 112015023481 A BR112015023481 A BR 112015023481A BR 112015023481 A2 BR112015023481 A2 BR 112015023481A2
Authority
BR
Brazil
Prior art keywords
controlled release
drug composition
liposome drug
release liposome
pharmaceutically acceptable
Prior art date
Application number
BR112015023481A
Other languages
English (en)
Other versions
BR112015023481A8 (pt
BR112015023481B1 (pt
Inventor
Chun Ou Han
Kan Pei
Tseng Yun-Long
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of BR112015023481A2 publication Critical patent/BR112015023481A2/pt
Publication of BR112015023481A8 publication Critical patent/BR112015023481A8/pt
Publication of BR112015023481B1 publication Critical patent/BR112015023481B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1/1 resumo composição de lipossoma de liberação controlada de fármaco a presente invenção refere-se a uma composição farmacêutica que compreende pelo menos um lipossoma, pelo menos um doador contra-íon polivalente ou um sal farmaceuticamente aceitável do mesmo, pelo menos um doador contra-íon monovalente ou um sal farmaceuticamente aceitável do mesmo, e um agente terapêutico anfipático. a presente invenção também se refere a métodos de inibição do crescimento de células de câncer, que compreendem a administração da composição farmacêutica aqui descrita.
BR112015023481-0A 2013-03-15 2014-03-15 Projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquososreferência cruzada para requerimentos relacionados BR112015023481B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792850P 2013-03-15 2013-03-15
US61/792,850 2013-03-15
PCT/US2014/029907 WO2014145187A1 (en) 2013-03-15 2014-03-15 Controlled drug release liposome composition

Publications (3)

Publication Number Publication Date
BR112015023481A2 true BR112015023481A2 (pt) 2017-07-18
BR112015023481A8 BR112015023481A8 (pt) 2019-12-03
BR112015023481B1 BR112015023481B1 (pt) 2022-12-20

Family

ID=51537897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023481-0A BR112015023481B1 (pt) 2013-03-15 2014-03-15 Projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquososreferência cruzada para requerimentos relacionados

Country Status (18)

Country Link
US (1) US9700511B2 (pt)
EP (1) EP2968146B1 (pt)
JP (2) JP6449848B2 (pt)
KR (1) KR101925507B1 (pt)
CN (2) CN105392474B (pt)
AU (1) AU2014233308B2 (pt)
BR (1) BR112015023481B1 (pt)
CA (1) CA2906149C (pt)
DK (1) DK2968146T3 (pt)
ES (1) ES2777223T3 (pt)
HK (1) HK1216010A1 (pt)
NZ (1) NZ711500A (pt)
PL (1) PL2968146T3 (pt)
RU (1) RU2712157C2 (pt)
SG (2) SG11201507110WA (pt)
TW (2) TWI592168B (pt)
WO (1) WO2014145187A1 (pt)
ZA (1) ZA201506214B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10220095B2 (en) * 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
CN106999419A (zh) * 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
WO2018136002A1 (en) * 2017-01-18 2018-07-26 Temasek Life Sciences Laboratory Limited Hyperstabilized liposomes increase targeting of mitotic cells
US20210275447A1 (en) * 2018-09-10 2021-09-09 Taiwan Liposome Co., Ltd. Sustained-release ophthalmic pharmaceutical compositions and uses thereof
CN112654348A (zh) * 2018-09-13 2021-04-13 台湾微脂体股份有限公司 含镇静药物的缓释药物组合物及其用途
TWI767149B (zh) * 2018-10-17 2022-06-11 台灣微脂體股份有限公司 含有免疫調節劑的緩釋藥物組合物及其用途
CN109260155B (zh) * 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
CN117750944A (zh) * 2021-09-30 2024-03-22 上海济煜医药科技有限公司 一种酒石酸长春瑞滨脂质体及其原料组合物、制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051183A1 (en) 1989-10-20 2001-12-13 Alza Corporation Liposomes with enhanced circulation time and method of treatment
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2003018018A2 (en) 2001-08-24 2003-03-06 Neopharm, Inc. Vinorelbine compositions and methods of use
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
EP1557429A1 (en) * 2004-01-23 2005-07-27 Vectron Therapeutics AG Site-directed coupling of proteins
CN103948545B (zh) 2004-05-03 2017-10-03 益普生生物制药公司 用于药物输送的脂质体
AU2005303389A1 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2007049278A2 (en) 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposomes and uses thereof
CN100375621C (zh) 2005-11-04 2008-03-19 唐星 长春瑞滨脂质微球注射液及其制备方法
CN100438855C (zh) 2006-01-19 2008-12-03 浙江大学 重酒石酸长春瑞滨脂质体及其冻干粉针与制备方法
CN100998562A (zh) 2006-12-31 2007-07-18 西安力邦医药科技有限责任公司 注射用长春瑞滨脂质体的制备方法
CN101129375B (zh) 2007-07-06 2010-12-22 浙江大学 长春瑞滨固体脂质纳米粒与其冻干制剂及制备方法
TW200922630A (en) * 2007-09-26 2009-06-01 Nat Health Research Institutes Liposome compositions useful for tumor imaging and treatment
CN101933904B (zh) 2009-07-01 2011-11-16 齐鲁制药有限公司 一种长春瑞滨长循环脂质体制剂及其制备方法
US20130052259A1 (en) * 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
CN101849915A (zh) 2010-05-26 2010-10-06 辽宁中医药大学 异长春花碱隐形脂质体冻干粉针剂及其制备方法
CN101843584B (zh) 2010-06-02 2012-05-30 北京大学 一种全反式维甲酸与脂质体的复合物及其应用

Also Published As

Publication number Publication date
EP2968146B1 (en) 2020-02-19
US20160030340A1 (en) 2016-02-04
TW201534353A (zh) 2015-09-16
CN109350600B (zh) 2021-10-29
SG10201707474XA (en) 2017-10-30
NZ711500A (en) 2020-05-29
US9700511B2 (en) 2017-07-11
BR112015023481A8 (pt) 2019-12-03
EP2968146A1 (en) 2016-01-20
TWI660749B (zh) 2019-06-01
BR112015023481B1 (pt) 2022-12-20
RU2712157C2 (ru) 2020-01-24
SG11201507110WA (en) 2015-10-29
JP6449848B2 (ja) 2019-01-09
DK2968146T3 (da) 2020-03-16
JP6752868B2 (ja) 2020-09-09
TWI592168B (zh) 2017-07-21
CN105392474A (zh) 2016-03-09
CA2906149A1 (en) 2014-09-18
CN105392474B (zh) 2019-01-08
RU2015135629A (ru) 2017-03-10
JP2016518340A (ja) 2016-06-23
KR20150129727A (ko) 2015-11-20
KR101925507B1 (ko) 2018-12-05
ES2777223T3 (es) 2020-08-04
JP2019055985A (ja) 2019-04-11
CA2906149C (en) 2020-09-15
CN109350600A (zh) 2019-02-19
PL2968146T3 (pl) 2020-06-29
HK1216010A1 (zh) 2016-10-07
EP2968146A4 (en) 2016-11-02
WO2014145187A1 (en) 2014-09-18
AU2014233308B2 (en) 2018-10-25
ZA201506214B (en) 2022-03-30
TW201500061A (zh) 2015-01-01
AU2014233308A1 (en) 2015-09-17
RU2015135629A3 (pt) 2018-03-06

Similar Documents

Publication Publication Date Title
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
CO2019008487A2 (es) Compuesto de quinazolina
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112018014027A2 (pt) composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
EP4324521A3 (en) Treatment of fabry disease in ert-naive and ert-experienced patients
IN2014MN02214A (pt)
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
PH12016502352A1 (en) Pharmaceutical composition
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
BR112018009413A2 (pt) formulação oral sólida e método para preparar a formulação oral sólida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2014, OBSERVADAS AS CONDICOES LEGAIS